These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6724125)

  • 1. A comparison of the bioavailability of two carbamazepine preparations (200 and 400 mg tablets).
    Monaco F; Porcella V
    J Int Med Res; 1984; 12(2):108-13. PubMed ID: 6724125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients.
    Morselli PL; Monaco F; Gerna M; Recchia M; Riccio A
    Epilepsia; 1975 Dec; 16(5):759-64. PubMed ID: 1222752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative bioavailability of carbamazepine in 100 mg and 200 mg tablets.
    Smith GA; Hooper WD; Tyrer JH; Eadie MJ; Werth B
    Clin Exp Pharmacol Physiol; 1979; 6(1):37-40. PubMed ID: 761426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability of two carbamazepine tablets.
    Glende M; Hüller H; Mai I; Migulla H; Prümke J; Schumann G
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):631-3. PubMed ID: 6668101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation.
    Maas B; Garnett WR; Pellock JM; Comstock TJ
    Ther Drug Monit; 1987; 9(1):28-33. PubMed ID: 3576660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bioavailability of carbamazepine.
    Cotter LM; Smith G; Hooper WD; Tyrer JH; Eadie MJ
    Proc Aust Assoc Neurol; 1975; 12():123-8. PubMed ID: 1215378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of stable labelled carbamazepine to study its kinetics during chronic carbamazepine treatment.
    Eichelbaum M; Köthe KW; Hoffmann F; von Unruh GE
    Eur J Clin Pharmacol; 1982; 23(3):241-4. PubMed ID: 6816617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the timing of food intake on the absorption and bioavailability of carbamazepine immediate-release tablets in beagle dogs.
    Xu CH; Cheng G; Liu Y; Tian Y; Yan J; Zou MJ
    Biopharm Drug Dispos; 2012 Jan; 33(1):30-8. PubMed ID: 22271001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions.
    Brewster ME; Anderson WR; Meinsma D; Moreno D; Webb AI; Pablo L; Estes KS; Derendorf H; Bodor N; Sawchuk R; Cheung B; Pop E
    J Pharm Sci; 1997 Mar; 86(3):335-9. PubMed ID: 9050802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and central side effects of different carbamazepine tablets.
    Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):226-32. PubMed ID: 3997307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences.
    Hoffmann C; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Möritz KU; Siegmund W
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):496-503. PubMed ID: 9401830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy.
    Hartley R; Aleksandrowicz J; Bowmer CJ; Cawood A; Forsythe WI
    J Pharm Pharmacol; 1991 Feb; 43(2):117-9. PubMed ID: 1672895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients.
    Thakker KM; Mangat S; Garnett WR; Levy RH; Kochak GM
    Biopharm Drug Dispos; 1992 Nov; 13(8):559-69. PubMed ID: 1421050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the biological availability of 2 carbamazepine preparations].
    Niedzielska K; Rosnowska M; Kuran W
    Neurol Neurochir Pol; 1986; 20(5):415-20. PubMed ID: 3295573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possibilities for the in vitro determination of bioavailability. 4. Comparison of the carbamazepine preparations Finlepsin and Tegretol].
    Fürst W; Neubert R; Buchmann E
    Pharmazie; 1984 Mar; 39(3):185-6. PubMed ID: 6728891
    [No Abstract]   [Full Text] [Related]  

  • 17. Carbamazepine: a clinical biopharmaceutical study.
    Dam M; Christiansen J; Kristensen CB; Helles A; Jaegerskou A; Schmiegelow M
    Eur J Clin Pharmacol; 1981; 20(1):59-64. PubMed ID: 7308274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability of two commercial preparations of carbamazepine tablets.
    Anttila M; Kahela P; Panelius M; Yrjänä T; Tikkanen R; Aaltonen R
    Eur J Clin Pharmacol; 1979 Jul; 15(6):421-5. PubMed ID: 583039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Carbamazepine: the bioavailability of 4 oral pharmaceutical products].
    Saavedra I; Passalacqua A; Chávez H; Biagini L; Galdames D
    Rev Med Chil; 1990 Oct; 118(10):1123-8. PubMed ID: 2152631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive performances in newly referred patients with temporal lobe epilepsy: comparison with normal subjects in basal condition and after treatment with controlled-release carbamazepine.
    Gigli GL; Maschio M; Diomedi M; Placidi F; Silvestri G; Marciani MG
    Int J Neurosci; 1996 Nov; 88(1-2):97-107. PubMed ID: 9003968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.